ERBB2 and prostate carcinoma: Targeting properties of radiometal (111In)-labelled anti-HER2 affibody molecules ABY-025 was compared with the properties of [111In]In-CHX-A”-trastuzumab in prostate cancer DU-145 xenografts with low HER2 expression (Malmberg et al. 2011).